

=> file medline, cancerlit, caplus, uspatfull, biosis, confsci, embase
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 FULL ESTIMATED COST ENTRY SESSION
 0.42 0.42

FILE 'MEDLINE' ENTERED AT 11:54:59 ON 07 AUG 2002

FILE 'CANCERLIT' ENTERED AT 11:54:59 ON 07 AUG 2002

FILE 'CAPLUS' ENTERED AT 11:54:59 ON 07 AUG 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USACETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 11:54:59 ON 07 AUG 2002
 CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 11:54:59 ON 07 AUG 2002
 COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'CONFSCI' ENTERED AT 11:54:59 ON 07 AUG 2002
 COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'EMBASE' ENTERED AT 11:54:59 ON 07 AUG 2002
 COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

=> s tnf (a) fusion?
 L1 84 tnf (a) fusion?

=> s l1 and immunoglob?
 L2 32 l1 and immunoglob?

=> s tumor necrosis factor or tnf (a) fusion?
 L3 2 FILES SEARCHED...
 273044 TUMOR NECROSIS FACTOR OR TNF (A) FUSION?

=> s l3 and immunoglob?
 L4 16661 l3 and immunoglob?

=> s l4 and lt(a)beta or lymphotoxin(a)beta
 L5 1555 l4 and lt(a) beta or lymphotoxin(a) beta

=> s l5 and immunoglob?
 L6 392 l5 and immunoglob?

=> dup rem l6
 L7 PROCESSING COMPLETED FOR L6
 307 DUP REM L6 (85 DUPLICATES REMOVED)

=> s l7 not py=>1998
 L8 5 FILES SEARCHED...
 '1998' NOT A VALID FILED CODE
 49 l7 not py=>1998

=> d his
 (FILE 'HOME' ENTERED AT 11:53:49 ON 07 AUG 2002)

FILE 'MEDLINE, CANCERLIT, CAPLUS, USPATFULL, BIOSIS, CONFSCI, EMBASE'
 ENTERED AT 11:54:59 ON 07 AUG 2002

L1 84 s tnf (a) fusion?
 L2 32 s l1 and immunoglob?
 L3 273044 s tumor necrosis factor or tnf (a) fusion?
 L4 16661 s l3 and immunoglob?

L5 1555 S L4 AND LT(A)BETA OR LYMPHOTOXIN (A) BETA
 L6 392 S L5 AND IMMUNOGLOB?
 L7 307 DUP REM L6 (85 DUPLICATES REMOVED)
 L8 49 S L7 NOT PY=>1998

=> d 18 1-49

L8 ANSWER 1 OF 49 MEDLINE
 AN 1998014593
 DN 98014593 PubMed ID: 9354470
 TI Developing lymph nodes collect CD4+CD3- ITbeta+ cells that can
 differentiate to APC, NK cells, and follicular cells but not T or B cells.
 AU Medius R E; Rennert P; Weissman I L
 CS Department of Cell Biology and Immunology, Faculty of Medicine, Vrije
 Universiteit, Amsterdam, The Netherlands.. t.mediuss.cellmed.vu.nl
 NC C442551 (NCT)
 SO IMMUNITY, (1997 Oct) 7 (4) 493-504.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199711
 ED Entered STN: 19971224
 Last Updated on STN: 20000303
 Entered Medline: 19971121

L8 ANSWER 2 OF 49 MEDLINE
 AN 97461446 MEDLINE
 DN 97461446 PubMed ID: 9317127
 TI Characterization of lymphotoxin-alpha beta complexes on the surface of
 mouse lymphocytes.
 AU Browning J L; Sizing I D; Lawton P; Bourdon P R; Rennert P D; Majeau G R;
 Ambrose C M; Hession C; Miatkowski K; Griffiths D A; Ngam-ek A; Meier W;
 Benjamin C D; Hochman P S
 CS Department of Immunology, Biogen, Cambridge, MA 02142, USA..
 SO JOURNAL OF IMMUNOLOGY, (1997 Oct 1) 159 (7) 3288-98.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 199710
 ED Entered STN: 19971105
 Last Updated on STN: 19971105
 Entered Medline: 19971021

L8 ANSWER 3 OF 49 MEDLINE
 AN 97439486 MEDLINE
 DN 97439486 PubMed ID: 9295042
 TI Lymphotoxin but not tumor necrosis factor
 functions to maintain splenic architecture and humoral responsiveness in
 adult mice.
 AU Mackay F; Majeau G R; Lawton P; Hochman P S; Browning J L
 CS Department of Immunology, Inflammation and Cell Biology, Biogen,
 Cambridge, MA 02142, USA.. fabienne-mackay@biogen.com
 SO EUROPEAN JOURNAL OF IMMUNOLOGY, (1997 Aug) 27 (8) 2033-42.
 CY JOURNAL CODE: 1273201. ISSN: 0014-2980.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199709

ED Entered STN: 1971013
Last Updated on STN: 19971013
Entered Medline: 19970930

L8 ANSWER 4 OF 49 MEDLINE
AN 97278851 Pubmed ID: 9133428
DN 97278851
TI Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice.
AU Koni P A; Sacca R; Lawton P; Browning J L; Ruddie N H; Flavell R A
CS Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
NC R01 AI34404 (NIHID)
SO IMMUNITY. (1997 Apr) 6 (4) 491-500.
CY United States
DT Journal code: 9432918. ISSN: 1074-7613.
LA English
FS Priority Journals
EM 199705
ED Entered STN: 19970523
Last Updated on STN: 19970523
Entered Medline: 19970513

L8 ANSWER 5 OF 49 MEDLINE
AN 97180895 Pubmed ID: 9029113
DN 97180895
TI Activation of the lymphotoxin beta receptor by cross-linking induces chemokine production and growth arrest in A375 melanoma cells.
AU Degli-Esposti M A; Davis-Smith T; Din W S; Smolak P J; Goodwin R G; Smith C A
CS Department of Biochemistry, Immunex Corporation, Seattle, WA 98101, USA.
SO JOURNAL OF IMMUNOLOGY. (1997 Feb 15) 158 (4) 1756-62.
CY United States
DT Journal code: 2945117R. ISSN: 0022-1767.
LA English
FS Priority Journals
EM 199703
ED Entered STN: 19970313
Last Updated on STN: 19970313
Entered Medline: 19970305

L8 ANSWER 6 OF 49 MEDLINE
AN 97079154 Pubmed ID: 8920886
DN 97079154
TI Surface lymphotoxin alpha/beta complex is required for the development of peripheral lymphoid organs.
AU Rembert P D; Browning J L; Mebius R; Mackay F; Hochman P S
CS Biotogen Inc., Cambridge, Massachusetts 02142, USA.
SO JOURNAL OF EXPERIMENTAL MEDICINE. (1996 Nov 1) 184 (5) 1999-2006.
CY United States
DT Journal code: 2945109R. ISSN: 0022-1007.
LA English
FS Priority Journals
EM 199612
ED Entered STN: 19970128
Last Updated on STN: 19970128
Entered Medline: 19961230

L8 ANSWER 7 OF 49 MEDLINE

AN 97075125 MEDLINE
DN 97075125 Pubmed ID: 8917551
TI Disrupted splenic architecture, but normal lymph node development in mice expressing a soluble lymphotoxin-beta receptor-IgG1 fusion protein.
AU Ertinger R; Browning J L; Michie S A; van Ewijk W; McDevitt H O
CS Department of Microbiology and Immunology, Stanford University School of Medicine, CA 94305, USA.
NC A1-36535 (NIAID)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. (1996 Nov 12) 93 (23) 13102-7.
CY United States
DT Journal code: 7505876. ISSN: 0027-8424.
LA English
FS Priority Journals
EM 199612
ED Entered STN: 19970128
Last Updated on STN: 19970128
Entered Medline: 19961230

L8 ANSWER 8 OF 49 MEDLINE
AN 96235047 Pubmed ID: 8642347
DN 96235047
TI Differentiation of follicular dendritic cells and full antibody responses require tumor necrosis factor receptor-1 signaling.
AU Le Hir M; Bluethmann H; Kosco-Vilbois M H; Muller M; di Padova F; Moore M; Ryffel B; Eugster H P
CS Swiss Institute of Technology, Institute of Toxicology, Schwerzenbach, Switzerland.
SO JOURNAL OF EXPERIMENTAL MEDICINE. (1996 May 1) 183 (5) 2367-72.
CY United States
DT Journal code: 2985109R. ISSN: 0022-1007.
LA English
FS Priority Journals
EM 199607
ED Entered STN: 19960726
Last Updated on STN: 19970203
Entered Medline: 19960718

L8 ANSWER 9 OF 49 MEDLINE
AN 94316627 Pubmed ID: 7518925
DN 94316627
TI Tumor necrosis factor alpha is an autocrine growth factor for normal human B cells.
AU Bousiotis V A; Nadler L M; Strominger J L; Goldfeld A E
CS Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA.
NC CA-58735 (NCI)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. (1994 Jul 19) 91 (15) 7007-11.
CY United States
DT Journal code: 7505876. ISSN: 0027-8424.
LA English
FS Priority Journals
EM 199408
ED Entered STN: 19940905
Last Updated on STN: 19980206
Entered Medline: 19940822

L8 ANSWER 10 OF 49 MEDLINE
AN 93008266 MEDLINE
DN 93008266 PubMed ID: 1356634
TI Stimulation of γ FN-gamma, TNF-alpha, and TNF-beta secretion in IL-2-activated T cells: costimulatory roles for LFA-1, LFA-2, CD44, and CD45 molecules.

AU Chong A S; Boussey I A; Graf L H; Scuderi P
CS Department of General Surgery, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612.

NC 1 R29 CA53805-01A1 (NCI)
SO CELLULAR IMMUNOLOGY, (1992 Oct 1) 144 (1) 69-79.
Journal code: 1146405. ISSN: 0008-8749.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199210
ED Entered STN: 19530122
Last Updated on STN: 19970203
Entered Medline: 19921028

L8 ANSWER 11 OF 49 MEDLINE
AN 92368145 MEDLINE
DN 92368145 PubMed ID: 1503416
TI Properties of monoclonal antibodies to human tumor necrosis factor alpha (TNF alpha).

AU McLaughlin P J; Elwood N J; Russell S M; Andrew S M; McKenzie I F
CS Department of Immunology, University of Liverpool, U.K.
SO ANTICANCER RESEARCH, (1992 Jul-Aug) 12 (4) 1243-6.
Journal code: 8102988. ISSN: 0250-7005.

CY Greece
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199209
ED Entered STN: 19920925
Last Updated on STN: 19920925
Entered Medline: 19920917

L8 ANSWER 12 OF 49 MEDLINE
AN 92323605 MEDLINE
DN 92323605 PubMed ID: 1352484
TI IL-3 dependence of a Thy-110, B220+, IL-3 receptor-positive antigen-specific DTH-initiating clone.

AU Miller I; Ferreri N R; Ramahadran R; Askenase P W
CS Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510.

NC A1-12211 (NIAID)
SO CELLULAR IMMUNOLOGY, (1992 Aug) 143 (1) 154-69.
Journal code: 1216405. ISSN: 0008-8749.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199208
ED Entered STN: 19920821
Last Updated on STN: 19950206
Entered Medline: 19920811

L8 ANSWER 13 OF 49 MEDLINE
AN 92013169 MEDLINE
DN 92013169 PubMed ID: 1655911

TI Development and characterization of ouabain-resistant human fusion partners.

AU Ramachandra R N; Berzai I; Rector E S; Sehon A H
CS Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada
SO JOURNAL OF IMMUNOLOGICAL METHODS, (1991 Aug 28) 142 (1) 21-9.
Journal code: 1305440. ISSN: 0022-1759.

CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199111
ED Entered STN: 19920124
Last Updated on STN: 19970203
Entered Medline: 19911112

L8 ANSWER 14 OF 49 MEDLINE
AN 7711965 MEDLINE
DN 7711965 PubMed ID: 557069
TI Antibodies against human lymphokines: I. Methods for induction of antibodies capable of neutralizing stable (alpha) and unstable (beta) lymphotoxins released in vitro by activated human lymphocytes.

AU Lewis J E; Carmack C E; Yamamoto R; Granger G A
SO JOURNAL OF IMMUNOLOGICAL METHODS, (1977) 14 (2) 163-76.
Journal code: 1305440. ISSN: 0022-1759.

CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 197704
ED Entered STN: 19900313
Last Updated on STN: 19980206
Entered Medline: 19770425

L8 ANSWER 15 OF 49 CAPLUS COPYRIGHT 2002 ACS
AN 19971766060 CAPLUS
DN 128174120
TI Selective disruption of lymphotoxin ligands reveals a novel set of mucosal lymph nodes and unique effects on lymph node cellular organization

AU Renkert, Paul D.; Browning, Jeffrey L.; Hochman, Paula S.
CS Dep. Immunol./Inflammation, Biogen Inc., Cambridge, MA, 02142, USA
SO International Immunology (1997), 9(11), 1627-1639
CODEN: INIMEN. ISSN: 0953-8178

PB Oxford University Press
DT Journal
LA English

L8 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2002 ACS
AN 19971637139 CAPLUS
DN 127317914
TI Cytotoxic activities of recombinant soluble murine lymphotoxin-.alpha. and lymphotoxin-.alpha.-beta. complexes

AU Mackay, Fabienne; Boudon, Paul R.; Griffiths, David A.; Lawton, Pornsiri; Zafari, Mohammad; Douglas, Sizing, Irene; Miatkowski, Konrad; Ngam-ek Apinya; Benjamins, Christopher D.; Hessson, Catherine; Ambrose, Christine M.; Welter, Werner; Browning, Jeffrey L.; Protein Eng., Mol. Genetics, Biogen, Cambridge, MA, 02142, USA
SO Journal of Immunology (1997), 159(7), 3299-3310
CODEN: JOIMAJ. ISSN: 0022-1767

PB American Association of Immunologists
DT Journal
LA English

L8 ANSWER 17 OF 49 CAPLUS COPYRIGHT 2002 ACS
 L8 1997.254389 CALUS
 DN 126:276255
 TI Role of T cells in the mediation of Heymann nephritis. II. Identification of Th1 and cytotoxic cells in glomeruli
 AU Penny, Mark J.; Boyd, Rochelle A.; Hall, Bruce W.
 CS Dep. Medicine, Univ. New South Wales, Liverpool Hospital, New South Wales, Australia
 SO Kidney International (1997), 51(4), 1059-1068
 PB CODEN: KDVIAS, ISSN: 0085-2538
 LA Blackwell
 TI Journal
 LA English
 L8 ANSWER 18 OF 49 USPATFILL
 AN 97:117693 USPATFILL
 TI Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
 IN Le, Junming, Jackson Heights, NY, United States
 Vilcek, Jan, New York, NY, United States
 Daddona, Peter, Menlo Park, CA, United States
 Chrayeb, John, Thorndale, PA, United States
 Knight, David, Berwyn, PA, United States
 Siegel, Scott, Westborough, MA, United States
 PA New York University Medical Center, New York, NY, United States (U.S. corporation)
 PI Centocor, Inc., Malvern, PA, United States (U.S. corporation)
 AI US 5698195 19971216
 RLI US 1994-124799 19941018 (8)
 Ser. No. US 1994-192061, filed on 4 Feb 1994, now abandoned And Ser. No. US 1994-192061, filed on 4 Feb 1994, now abandoned, each Ser. No. US - which is a continuation-in-part of Ser. No. US 1993-10406, filed on 29 Jan 1993, now abandoned And Ser. No. US 1993-13413, filed on 2 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-943852, filed on 11 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-851606, filed on 18 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-670827, filed on 18 Mar 1991, now abandoned
 DT Utility
 FS Granted
 INCL INCLM: 424/133.100
 INCLS: 424/141.100; 424/145.100; 424/192.100; 514/825.000; 530/387.300;
 NCLM: 424/133.100
 NCLM: 424/133.100
 NCLM: 424/141.100; 424/142.100; 424/145.100; 514/825.000; 530/351.000;
 NCLM: 530/387.300; 530/388.100; 530/388.230
 IC [6]
 ICM: A61K039-315
 ICS: C07K016-24; C07K014-495; C12N015-13
 EXF 424/133.1; 424/141.1; 424/145.1; 424/192.1; 514/825; 530/387.3; 530/351;
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L8 ANSWER 19 OF 49 USPATFILL
 AN 97:86267 USPATFILL
 TI Lymphotoxin-beta, Lymphotoxin-beta, complexes, pharmaceutical preparations and therapeutic uses thereof
 IN Browning, Jeffrey, Brookline, MA, United States
 Ware, Carl F., Riverside, CA, United States
 PA Biogen, Inc., Cambridge, MA, United States (U.S. corporation)

PI The University of California, Oakland, CA, United States (U.S. corporation)
 AI US 5670149 19970923
 RLI US 1995-476489 19950606 (8)
 Continuation of Ser. No. US 1994-222614, filed on 1 Apr 1994, now abandoned which is a continuation-in-part of Ser. No. US 1990-544862, filed on 27 Jun 1990, now abandoned
 DT Utility
 FS Granted
 INCL INCLM: 424/130.100
 INCLS: 424/133.100; 424/139.100; 424/141.100; 424/142.100; 424/145.100;
 NCLM: 424/158.100; 435/069.500; 530/388.220; 530/388.240
 NCLM: 424/133.100; 424/139.100; 424/141.100; 424/142.100; 424/145.100;
 NCLM: 424/158.100; 435/069.500; 530/388.220; 530/388.240
 IC [6]
 ICM: A61K039-395
 EXF 435/69.5; 435/172.1; 435/320.1; 530/388.22; 530/388.24; 424/130.1;
 424/133.1; 424/139.1; 424/141.1; 424/142.1; 424/145.1; 424/158.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L8 ANSWER 20 OF 49 USPATFILL
 AN 97:75989 USPATFILL
 TI Lymphotoxin-beta, Lymphotoxin-beta, complexes, pharmaceutical preparations and therapeutic uses thereof
 IN Browning, Jeffrey, Brookline, MA, United States
 Ware, Carl F., Riverside, CA, United States
 PA Biogen, Inc., Cambridge, MA, United States (U.S. corporation)
 PI University of California, Oakland, CA, United States (U.S. corporation)
 AI US 5661004 19970826
 RLI US 1995-484272 19950607 (8)
 Continuation of Ser. No. US 1994-222614, filed on 1 Apr 1994, now abandoned which is a continuation of Ser. No. US 1992-990104, filed on 4 Dec 1992, now abandoned which is a continuation of Ser. No. US 1990-544862, filed on 27 Jun 1990, now abandoned
 DT Utility
 FS Granted
 INCL INCLM: 435/069.100
 INCLS: 435/240.200; 536/023.500
 NCLM: 435/069.100
 NCLM: 435/325.000; 435/358.000; 435/366.000; 435/372.300; 536/023.500
 IC [6]
 ICM: C12N015-00
 ICS: C12N015-11; C12N015-85
 EXF 435/69.5; 435/69.1; 435/240.2; 536/23.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L8 ANSWER 21 OF 49 USPATFILL
 AN 97:70718 USPATFILL
 TI Methods of treating TNF-alpha-mediated Crohn's disease using chimeric anti-TNF antibodies
 IN Le, Junming, Jackson Heights, NY, United States
 Vilcek, Jan, New York, NY, United States
 Daddona, Peter, Palo Alto, CA, United States
 Chrayeb, John, Thorndale, PA, United States
 Knight, David, Berwyn, PA, United States
 Siegel, Scott A., Westborough, MA, United States
 PA New York University Medical Center, New York, NY, United States (U.S. corporation)
 PI Centocor, Inc., Malvern, PA, United States (U.S. corporation)

AI US 1994-192101; 19940204 (8)
 Continuation-in-part of Ser. No. US 1993-10406, filed on 26 Jan 1993,
 now abandoned And Ser. No. US 1993-13413, filed on 2 Feb 1993, now
 abandoned which is a continuation-in-part of Ser. No. US 1992-943852,
 filed on 11 Sep 1992, now abandoned which is a continuation-in-part of
 Ser. No. US 1992-853606, filed on 18 Mar 1992, now abandoned which is a
 continuation-in-part of Ser. No. US 1991-670827, filed on 18 Mar 1991,
 now abandoned
 DT Utility
 FS Granted
 LN.CNT 5251
 INCL INCLM: 424/133.100
 INCLS: 424/144.100; 424/139.100; 435/069.100; 435/069.600; 435/069.700;
 530/387.300; 530/388.230
 NCL NCLM: 424/133.100
 NCLS: 424/135.100; 424/145.100; 435/069.100; 435/069.600; 435/069.700;
 530/387.300; 530/388.230
 IC [6]
 ICM: A61K039-395
 ICS: C12P021-05; C12P021-04; C12P021-08
 EXF 424/158.1; 424/810; 435/69.6; 435/172.2; 435/70.21; 435/240.27; 935/15;
 530/388.23; 530/389.2; 530/804
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L8 ANSWER 22 OF 49 USPATFULL
 AN 97:56799 USPATFULL
 TI Tumor necrosis factor binding ligands
 IN Rathjen, Deborah Ann, New South Wales, Australia
 PA Aston, Roger, Gloucester, Great Britain
 PI Peptide Technology Ltd., Australia (non-U.S. corporation)
 AI US 5644034 19970701
 US 1994-344133 19941123 (8)
 RLI Continuation-in-part of Ser. No. US 1992-828956, filed on 18 Feb 1992,
 now abandoned
 PRAI AU 1989-5662 19890807
 AU 1989-7576 19891124
 WO 1990-AU337 19900807
 DT Utility
 FS Granted
 LN.CNT 1493
 INCL INCLM: 530/388.230
 INCLS: 530/388.240; 530/389.100; 530/389.200
 NCL NCLM: 530/388.230
 NCLS: 530/388.240; 530/389.100; 530/389.200
 IC [6]
 ICM: C07K016-24
 ICS: C12N005-12
 EXF 530/388.23; 530/388.24; 530/389.1; 530/389.2; 530/350; 530/351;
 435/240.27
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L8 ANSWER 23 OF 49 USPATFULL
 AN 97:54201 USPATFULL
 TI Tumor necrosis factor inhibitors
 IN Heaven, George A., Malvern, PA, United States
 PA Centocor, Inc., Malvern, PA, United States (U.S. corporation)
 PI US 5641751 19970624
 US 1995-432694 19950501 (8)
 AI US 1995-432694
 DT Utility
 FS Granted
 LN.CNT 1235
 INCL INCLM: 514/013.100
 INCLS: 514/012.100; 514/014.000; 514/015.000; 514/016.000; 514/017.000;
 514/018.100; 530/324.000; 530/325.000; 530/326.000; 530/327.000;

NCL NCLM: 530/328.000; 530/329.000; 530/330.000
 INCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000;
 514/018.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000;
 530/328.000; 530/329.000; 530/330.000
 IC [6]
 ICM: A61K038-00
 ICS: C07K007-00
 EXF 514/12.18; 530/327; 530/328; 530/329; 530/330; 530/326
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L8 ANSWER 24 OF 49 USPATFULL
 AN 97:8000 USPATFULL
 TI Tumor necrosis factor muteins
 IN Banner, David, Basle, Switzerland
 PA Lesslauer, Werner, Riehen, Switzerland
 PI Lotcher, Hansruedi, Mohlin, Switzerland
 Stuber, Dietrich, Grenzach-Wyhlen, Germany, Federal Republic of
 Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)
 AI US 5597899 19970128
 US 1994-217529 19940324 (8)
 PRAI EP 1993-810224 19930329
 DT Utility
 FS Granted
 LN.CNT 1506
 INCL INCLM: 530/351.000
 INCLS: 435/069.500; 435/069.100; 530/402.000
 NCL NCLM: 530/351.000
 NCLS: 435/069.100; 435/069.500; 530/402.000
 IC [6]
 ICM: C07K014-525
 ICS: C12P021-06
 EXF 530/351; 435/69.1; 435/69.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L8 ANSWER 25 OF 49 USPATFULL
 AN 96:43651 USPATFULL
 TI Tumor necrosis factor inhibitors
 IN Heaven, George A., Malvern, PA, United States
 PA Kruszynski, Marian, West Chester, PA, United States
 Mervic, Miljenko, King of Prussia, PA, United States
 Weber, Robert W., Downingtown, PA, United States
 PI Centocor, Inc., Malvern, PA, United States (U.S. corporation)
 AI US 5519000 19960521
 US 1994-221580 19940401 (8)
 DT Utility
 FS Granted
 LN.CNT 1410
 INCL INCLM: 514/012.000
 INCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000;
 514/018.000; 530/324.000; 530/326.000; 530/328.000; 530/329.000;
 530/330.000
 NCL NCLM: 514/012.000
 NCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000;
 514/018.000; 530/324.000; 530/326.000; 530/328.000; 530/329.000;
 530/330.000
 IC [6]
 ICM: A61K038-00
 ICS: C07K007-04; C07K014-00
 EXF 530/324; 530/326; 530/328; 530/329; 530/330; 514/12; 514/13; 514/14;
 514/15; 514/16; 514/17; 514/18
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L8 ANSWER 26 OF 49 USPATFULL

AN 96:29667 USPT/FULL
 TI Tumor necrosis factor inhibitors
 IN Heavner, George A., Malvern, PA, United States
 PI Centecor, Inc., Malvern, PA, United States (U.S. corporation)
 PA US 5506340
 AI US 1994-221581 19960409
 DT Utility
 FS Granted
 LN.CNT 1053
 INCL INCLM: 530/324.000
 INCLS: 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000;
 NCL NCLM: 530/324.000
 NCLS: 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000;
 IC [6]
 ICM: C07K005-0)
 ICS: C07K007-0); C07K017-00
 EXF 514/12-18; 530/324-330
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 27 OF 49 USPT/FULL
 AN 96:7781 USPT/FULL
 TI Tumor necrosis factor inhibitors
 IN Heavner, George A., Malvern, PA, United States
 PA Centecor, Inc., Malvern, PA, United States (U.S. corporation)
 PI US 5466595 19960123
 AI US 1994-221583 19940401 (8)
 DT Utility
 FS Granted
 LN.CNT 2105
 INCL INCLM: 530/324.000
 INCLS: 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000;
 NCL NCLM: 530/324.000
 NCLS: 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000;
 IC [6]
 ICM: C07K005-00
 ICS: C07K007-00; C07K017-00
 EXF 530/324-330; 511/12-18
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 28 OF 49 USPT/FULL
 AN 95:57890 USPT/FULL
 TI Method of activating T cells with lymphokine SAF
 IN Defreitas, Elaine, Villanova, PA, United States
 PA Abrams, J. Todd, Narberth, PA, United States
 PI US 5427781 19950627
 AI US 1993-84996 19930702 (8)
 RLI Division of Ser. No. US 1990-628621, filed on 10 Dec 1990, now patented,
 Pat. No. US 5225535 which is a continuation-in-part of Ser. No. US
 1988-284558, filed on 15 Dec 1988, now abandoned
 DT Utility
 FS Granted
 LN.CNT 718
 INCL INCLM: 424/851.600
 INCLS: 530/350.000; 530/351.000; 514/002.000; 514/008.000; 514/012.000;
 NCL NCLM: 424/085.100
 NCLS: 424/198.100; 424/545.000; 435/240.200
 IC [6]
 ICM: A61K037-66
 ICS: 514/012.000; 530/350.000; 530/351.000

EXF ICM: A61K038-19
 ICS: C07K014-52
 530/351; 530/350; 424/85.1; 424/545; 424/198.1; 514/2; 514/8; 514/12;
 435/240.2

L8 ANSWER 29 OF 49 USPT/FULL
 AN 93:54849 USPT/FULL
 TI Lymphokine SAF and method of making
 IN Defreitas, Elaine C., Villanova, PA, United States
 PA Abrams, J. Todd, Narberth, PA, United States
 PI The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)
 AI US 5225535 19930706
 RLI US 1990-628621 19901210 (7)
 now abandoned
 DT Utility
 FS Granted
 LN.CNT 678
 INCL INCLM: 530/351.000
 INCLS: 424/085.100
 NCL NCLM: 530/351.000
 NCLS: 424/085.100
 IC [5]
 ICM: C07K015-00
 ICS: 530/351; 424/85.1
 EXF 530/351; 424/85.1

L8 ANSWER 30 OF 49 USPT/FULL
 AN 93:22478 USPT/FULL
 TI Temporal gamma-interferon administration for allergies
 IN Jardieu, Paula M., Belmont, CA, United States
 PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
 PI US 5196191 19930323
 AI US 1991-774429 19911010 (7)
 RLI Continuation of Ser. No. US 1989-325406, filed on 17 Mar 1989, now
 patented, Pat. No. US 5112605
 DT Utility
 FS Granted
 LN.CNT 432
 INCL INCLM: 424/085.500
 NCL NCLM: 424/085.500
 IC [5]
 ICM: A61K037-66
 ICS: 424/85.5
 EXF 424/85.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 31 OF 49 USPT/FULL
 AN 92:38161 USPT/FULL
 TI Temporal gamma-interferon administration for allergies
 IN Jardieu, Paula, Belmont, CA, United States
 PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
 PI US 5112605 19920512
 AI US 1989-325406 19890317 (7)
 DT Utility
 FS Granted
 LN.CNT 440
 INCL INCLM: 424/085.500
 NCL NCLM: 424/085.500
 IC [5]
 ICM: A61K037-66
 ICS: 424/85.5
 EXF 424/85.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 32 OF 49 USPATFULL
 AN 91:48551 USPTFULL
 TI Transient expression system for producing recombinant protein
 IN Gorman, Corneia M., San Francisco, CA, United States
 PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
 PI US 5034939 19910618
 AI US 1987-10171: 19870925 (7)
 RLI Continuation-in-part of Ser. No. US 1987-71674, filed on 9 Jul 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-907185, filed on 12 Sep 1986, now abandoned
 DT Utility
 FS Granted
 LN.CNT 1597
 INCL INCLM: 435/065.100
 INCL INCLM: 435/172.300
 NCL INCLM: 435/065.100
 NCLM: 435/461.000; 435/466.000
 IC [5]
 ICM: C12N015-67
 EXF 435/68; 435/172.3; 435/235; 435/320; 435/69.1; 935/32; 935/34; 935/27; 935/56
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 33 OF 49 USPATFULL
 AN 90:59326 USPATFULL
 TI Methods and compositions for the treatment of lung conditions
 IN Ammann, Arthur O., San Rafael, CA, United States
 PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
 PI US 4944941 19900731
 AI US 1987-83605 19870807 (7)
 DT Utility
 FS Granted
 LN.CNT 921
 INCL INCLM: 424/085.500
 INCL INCLM: 424/085.100
 NCL INCLM: 424/085.500
 NCLM: 424/085.100
 IC [5]
 ICM: A61K037-6;
 ICS: A61K037-00
 EXF 424/85.1; 442/85.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 34 OF 49 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1997:145063 BIOSIS
 DN PREV199799444266
 TI Multiple pathways for lymphotoxin (LT) to affect lymph node genesis and lymphocyte organization.
 AU Remmert, P. D.; Irowling, J. L.; Hochman, P. S.
 CS Biogen Inc., Cambridge, MA USA
 SO Journal of Allergy and Clinical Immunology, (1997) Vol. 99, No. 1 PART 2, pp. S379.
 Meeting Info.: Joint Meeting of the American Academy of Allergy, Asthma and Immunology, the American Association of Immunologists and the Clinical Immunology Society San Francisco, California, USA February 21-26, 1997
 ISSN: 0091-6749
 DT Conference; Abstract
 LA English

L8 ANSWER 35 OF 49 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1996:570577 BIOSIS
 DN PREV199799285258

TI **Tumor necrosis factor receptor-1 signaling**
 is required for differentiation of follicular dendritic cells, germinal center formation, and full antibody responses.
 AU Le Hir, Michel (1); Bluthmann, Horst; Kosco-Vilpois, Marie H.; Mueller, Mathias; Di Padova, Franco; Moore, Mark; Kyte, Bernhard; Eugster, Hans-Peter
 CS (1) Inst. Toxicology, Schorenstrasse 16, CH-8603 Schwerzenbach Switzerland
 SO Journal of Inflammation, Vol. 47, No. 1-2, pp. 76-80.
 ISSN: 1078-7852.
 DT Article
 LA English

L8 ANSWER 36 OF 49 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1996:351442 BIOSIS
 DN PREV199699073798
 TI Normal development of lymph nodes is disrupted by soluble LT
 AU beta receptor-Ig fusion protein.
 AU Remmert, P. J.; Browning, J. L.; Hochman, P. S.
 CS Biogen, Inc., 14 Cambridge Cent., Cambridge, MA 02142 USA
 SO European Cytokine Network, (1996) Vol. 7, No. 2, pp. 167.
 Meeting Info.: 6th International Tumor Necrosis Factor Congress Rhodes, Greece May 8-12, 1996
 ISSN: 1148-5493.
 DT Conference
 LA English

L8 ANSWER 37 OF 49 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1993:74879 BIOSIS
 DN PREV199395039379
 TI Insults in transgenic mice expressing tumor necrosis factor beta (lymphotoxin) in the pancreas.
 AU Picarella, Dominic E. (1); Kratz, Alexander; Li, Chang-Ben; Ruddle, Nancy H.; Flavell, Richard A. (1)
 CS (1) Sect. Immunobiol., Yale Univ. Sch. Med., New Haven, Conn. 06510 USA
 SO Proceedings of the National Academy of Sciences of the United States of America, (1992) Vol. 89, No. 21, pp. 10036-10040.
 ISSN: 0027-8424.
 DT Article
 LA English

L8 ANSWER 38 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 97358725 EMBASE
 DN 1997358725
 TI Peyer's patch organogenesis - Cytokines rule, ok?
 AU Mayrhofer G.
 CS Prof. G. Mayrhofer, Adelaide/Arthritis Res. Lab. Univ., Hanson Centre for Cancer Research, Inst. of Medical/Veterinary Science, Adelaide, SA, Australia
 SO Gut, (1997) 41/5 (707-709).
 Refs: 20
 ISSN: 0017-5749 CODEN: GUTTAK
 CY United Kingdom
 DT Journal; General Review
 FS 021 Developmental Biology and Teratology
 LA English
 SL English

L8 ANSWER 39 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 97267130 EMBASE
 DN 1997267130
 TI Adenovirus-mediated blockade of lymphotoxin-beta.
 inhibits the induction of contact sensitivity in mice.
 AU Trueb R.M.; Brown G.R.; Dougherty I.; Valdez-Silva M.; Cruz P.D. Jr.

- CS P.D. Cruz Jr., Department of Dermatology, UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-9069, United States.
pcruzmednet.swmed.edu
Experimental Dermatology, (1997) 6/4 (175-180).
Refs: 13
- SO ISSN: 0906-6705 CODEN: EXDEBY
- CY Denmark
- DT Journal; Article
- FS 013 Dermatology and Venereology
- LA 026 Immunology, Serology and Transplantation
- SL English
- L8 ANSWER 40 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 97153057 EMBASE
DN 1997153057
- TI Human TNF receptor-associated factor 5 (TRAF5): cDNA cloning, expression and assignment of the TRAF5 gene to chromosome 1q32.
- AU Nakano H.; Shindō M.; Yamada K.; Yoshida M.C.; Santee S.M.; Ware C.F.; Jenkins N.A.; Gilbert D.J.; Yagita H.; Copeland N.G.; Okumura K. H. Nakano, Department of Immunology, Juntendo Univ. School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113, Japan. hnakanomed.juntendo.ac.jp
- CS Genomics, (1997) 42/1 (26-32).
Refs: 44
- SO ISSN: 0888-7543 CODEN: GNMCEP
- CY United States
- DT Journal; Article
- FS 022 Human Genetics
- LA English
- SL English
- L8 ANSWER 41 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 97139554 EMBASE
DN 1997139554
- TI Lymphotoxin- α -deficient and TNF receptor-1-deficient mice define developmental and functional characteristics of germinal centers.
- AU Matsumoto M.; Fu Y.-X.; Molina H.; Chaplin D.D. D.D. Chaplin, Center for Immunology, Division of Allergy and Immunology, Washington Univ. School of Medicine, 660 South Euclid Ave, St Louis, MO 63110, United States. chaplin@wustl.edu
- CS Immunological Reviews, (1997) 156/- (137-144).
Refs: 40
- SO ISSN: 0105-2896 CODEN: IMREED
- CY Denmark
- DT Journal; General Review
- FS 026 Immunology, Serology and Transplantation
- LA 029 Clinical Biochemistry
- SL English
- L8 ANSWER 42 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 97095494 EMBASE
DN 1997095494
- TI Lymphotoxin- β receptor signaling complex: Role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor κ B
- AU Vahedi T.L.; Vahedi S.L.; Force W.R.; Walter B.N.; Mosialos G.; Kleit E.; Reeds J.C.; Ware C.F. C.F. Ware, Division of Molecular Immunology, La Jolla Allergy/Immunology Inst., 10355 Science Center Drive, San Diego, CA 92121, United States
- CS Proceedings of the National Academy of Sciences of the United States of America, (1997) 94/6 (2460-2465).
Refs: 62
- SO ISSN: 0027-8424 CODEN: PNASA6
- CY United States
- DT Journal; Article
- FS 029 Clinical Biochemistry
- LA English
- SL English
- L8 ANSWER 43 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 97040304 EMBASE
DN 1997040304
- TI Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NF- κ B activation.
- AU Aizawa S.; Nakano H.; Ishida T.; Horie R.; Nagai M.; Ito K.; Yagita H.; Okumura K.; Inoue J.; Watanabe T. T. Watanabe, Dept. of Pathology, Inst. of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108, Japan.
tnabe@ims.u-tokyo.ac.jp
- CS Journal of Biological Chemistry, (1997) 272/4 (2042-2045).
Refs: 28
- SO ISSN: 0021-9258 CODEN: JBCHA3
- CY United States
- DT Journal; Article
- FS 029 Clinical Biochemistry
- LA English
- SL English
- L8 ANSWER 44 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 97025237 EMBASE
DN 1997025237
- TI T cell cytokines and disease prevention.
- AU Wood P.R.; Seow H.-F. H.-F. Seow, CSIRO Division of Animal Health, Private Bag No. 1, Parkville, Vic. 3052, Australia
- CS Veterinary Immunology and Immunopathology, (1996) 54/1-4 (33-44).
Refs: 86
- SO ISSN: 0165-2427 CODEN: VIIMDS
- CY Netherlands
- DT Journal; Conference Article
- FS 026 Immunology, Serology and Transplantation
- LA English
- SL English
- L8 ANSWER 45 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 96275259 EMBASE
DN 1996275259
- TI Adenoviral gene transfer of a lymphotoxin- β . Inhibitor protein versus gene-targeted lymphotoxin- α . Knockout: Effect on delayed-type cutaneous hypersensitivity versus abnormal development of peripheral lymphoid tissues in lymphotoxin- α -deficient mice.
- AU Trueb R.M.; Cruz P.D.; Dougherty I.; Brown G.; Van Hufel C.; Valdez-Silva M.; Beutler B. B. Beutler, Department of Dermatology, University Hospital, Zurich, Switzerland
- CS Department of Dermatology, (1996) 133/2 (174).
ISSN: 1018-8665 CODEN: DERRAG
- SO Switzerland
- DT Journal; Conference Article
- FS 013 Dermatology and Venereology
- LA English
- SL English
- L8 ANSWER 46 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 96266842 EMBASE
DN 1996266842

TI Prolinflammatory responses are efficiently induced by homotrimeric but not heterotrimeric lymphotoxin ligands.
 AU Hochman P.S.; Mijean G.R.; Mackay F.; Browning J.L.
 CS Biogen, 14 Cambridge Center, Cambridge, MA 02142, United States
 SO Journal of Inflammation, (1995) 46/4 (220-234).
 ISSN: 1078-7852 CODEN: JOINF8
 CY United States
 DT Journal; Article
 FT 016 Cancer
 FS 026 Immunology, Serology and Transplantation
 DN 030 Pharmacology
 LA 037 Drug Literature Index
 SL English

L8 ANSWER 47 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 95218248 EMBAS:
 DN 1995218248
 TI Mechanism of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.
 AU Marzocha K.; Blumvenu J.; Colffier B.; Salles G.
 CS Service d'Hematologie, Centre Hospitalier Lyon-Stud, 69495 Pierre-Benite Cedex, France
 SO European Cytokine Network, (1995) 6/2 (83-96).
 ISSN: 1148-5493 CODEN: ECYNEJ
 CY France
 DT Journal; General Review
 FS 026 Immunology, Serology and Transplantation
 DN 029 Clinical Biochemistry
 LA English
 SL English

L8 ANSWER 48 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 95006487 EMBAS:
 DN 1995006487
 TI Characterization of surface lymphotoxin forms: Use of specific monoclonal antibodies and soluble receptors.
 AU Browning J.L.; Iougas I.; Ngan-Ek A.; Bourdon P.R.; Ehrenfels B.N.; Matkowski K.; Atari M.; Yamaglia A.M.; Lawton P.; Welter W.; Benjamin C.P.; Heession C.
 CS Department of Cell Biology, Biogen Inc., 14 Cambridge Center, Cambridge, MA 02142, United States
 SO Journal of Immunology, (1995) 154/1 (33-46).
 ISSN: 0022-1767 CODEN: JOIMA3
 CY United States
 DT Journal; Article
 FS 026 Immunology, Serology and Transplantation
 DN 029 Clinical Biochemistry
 LA English
 SL English

L8 ANSWER 49 OF 49 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 94102228 EMBASE
 DN 1994102228
 TI Tumor necrosis factor alpha (TNF-alpha.) and TNF-beta. and their receptors in experimental cutaneous leishmaniasis.
 AU De Kossodo S.; Gerau G.E.; Louis J.A.; Muller I.
 CS Department of Dermatology, Texas Univ., Southwestern Med. Center, 5323 Harry Hines Blvd., Dallas, TX 75235-9050, United States
 SO Infection and Immunity, (1994) 62/4 (1414-1420).
 ISSN: 0019-9567 CODEN: INFIBR
 CY United States
 DT Journal; Article
 FS 004 Microbiology

026 Immunology, Serology and Transplantation
 029 Clinical Biochemistry
 LA English
 SL English

=> d 18 36 all

L8 ANSWER 36 OF 49 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1996:351442 BIOSIS
 DN PREV199699073798
 TI Normal development of lymph nodes is disrupted by soluble LT beta receptor-Ig fusion protein.
 AU Renner, P. J.; Browning, J. L.; Hochman, P. S.
 CS Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142 USA
 SO European Cytokine Network, (1996) Vol. 7, No. 2, pp. 167.
 Meeting Info: 6th International Tumor Necrosis Factor Congress Rhodes, Greece May 8-12, 1996
 ISSN: 1148-5493.
 DT Conference
 LA English
 CC General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annals 00520
 Biochemical Studies - Carbohydrates 10068
 Biochemical Studies - Proteins, Peptides and Amino Acids 10064
 Biophysics - Membrane Phenomena *10508
 Cardiovascular System - Physiology and Biochemistry *14504
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
 Endocrine System - General *17002
 Developmental Biology - Embryology - General and Descriptive *25502
 Developmental Biology - Embryology - Morphogenesis, General *25508
 Immunology and Immunochimistry - General; Methods *34502
 Muridae *86375

BC Major Concepts
 IT Blood and Lymphatics (Transport and Circulation); Cardiovascular System (Transport and Circulation); Development; Endocrine System (Chemical Coordination and Homeostasis); Immune System (Chemical Coordination and Homeostasis); Membranes (Cell Biology)

IT Miscellaneous Descriptors
 EMBRYONIC CIRCULATION; IMMUNOGLOBULIN G; LYMPHOTOXIN -BETA; MEETING ABSTRACT; MOUSE YOLK SAC; TUMOR NECROSIS FACTOR

ORGN Super Taxa
 Muridae; Rodentia, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 Muridae (Muridae)
 ORGN Organism Superterus
 animals; chordates; mammals; nonhuman vertebrates; nonhuman mammals; rodents; vertebrates

=> d his

(FILE 'HOME' ENTERED AT 11:53:49 ON 07 AUG 2002)

FILE 'MEDLINE, CANCERLIT, CAPLUS, USPATFULL, BIOSIS, CONFSCI, EMBASE' ENTERED AT 11:54:59 ON 07 AUG 2002

84 S TNF (A) FUSION?
 32 S LT AND IMMUNOGLOB?
 273044 S TUMOR NECROSIS FACTOR OR TNF (A) FUSION?
 16661 S LT AND IMMUNOGLOB?
 1555 S LT AND LT(A)BETA OR LYMPHOTOXIN(A)BETA
 392 S LT AND IMMUNOGLOB?

L7 307 DUP ITEM L6 (85 DUPLICATES REMOVED)
L8 49 S L7 NOT PY=>1998
=> s lt(a)beta or lymphotoxin beta and fusion
L9 941 LT(A) BETA OR LYMPHOTOXIN BETA AND FUSION
=> s l9 and immunoglob? or lg
L10 138626 L9 ANT IMMUNOLOG? OR IG
=> s l9 and lg
L11 177 L9 ANT IG
=> dup rem l11
PROCESSING COMPLETED FOR L11
L12 131 DUP REM L11 (46 DUPLICATES REMOVED)
=> s l12 not py=>1998
'1998' NOT A VALID FIELD CODE
L13 9 L12 NOT PY=>1998
=> d l13 1-9
L13 ANSWER 1 OF 9 MEDLINE
AN 1998079319 MEDLINE
DN 98079319 PubMed ID: 9418124
TI Selective disruption of lymphotoxin ligands reveals a novel set of mucosal
AU lymph nodes and unique effects on lymph node cellular organization.
AU Renmet P D; Browning J L; Hochman P S
CS Department of Immunology/Inflammation, Biogen Inc., Cambridge, MA 02142,
USA.
SO INTERNATIONAL IMMUNOLOGY, (1997 Nov) 9 (11) 1627-39.
CY ENGLAND: United Kingdom
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199802
ED Entered STN: 19980306
Last Updated on STN: 19980220
Entered Medline: 19980220
L13 ANSWER 2 OF 9 MEDLINE
AN 97461447 MEDLINE
DN 97461447 PubMed ID: 9317128
TI Cytotoxic activities of recombinant soluble murine lymphotoxin-alpha and
AU lymphotoxin-alpha beta complexes.
AU Mackay F; Bourdon P R; Griffiths D A; Lawton P; Zafari M; Sizing I D;
Mackowski K; Ngan-ek A; Benjamin C D; Hession C; Ambrose C M; Meier W;
Browning J L
CS Department of Immunology, Biogen, Cambridge, MA 02142, USA.
SO JOURNAL OF IMMUNOLOGY, (1997 Oct 1) 159 (7) 3299-310.
CY United States
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199710
ED Entered STN: 1997105
Last Updated on STN: 19971105
Entered Medline: 19971021
L13 ANSWER 3 OF 9 MEDLINE
AN 97461446 MEDLINE
DN 97461446 PubMed ID: 9317127

TI Characterization of lymphotoxin-alpha beta complexes on the surface of
mouse lymphocytes.
AU Browning J L; Sizing I D; Lawton P; Bourdon P R; Renmet P D; Majean G R;
Ambrose C M; Hession C; Mackowski K; Griffiths D A; Ngan-ek A; Meier W;
Benjamin C D; Hochman P S
CS Department of Immunology, Biogen, Cambridge, MA 02142, USA.
Jelt.Browning@biogen.com
SO JOURNAL OF IMMUNOLOGY, (1997 Oct 1) 159 (7) 3288-98.
CY United States
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199710
ED Entered STN: 1997105
Last Updated on STN: 1997105
Entered Medline: 19971021
L13 ANSWER 4 OF 9 MEDLINE
AN 97439486 MEDLINE
DN 97439486 PubMed ID: 9295042
TI Lymphotoxin but not tumor necrosis factor functions to maintain splenic
AU architecture and humoral responsiveness in adult mice.
AU Mackay F; Majean G R; Lawton P; Hochman P S; Browning J L
CS Department of Immunology, Inflammation and Cell Biology, Biogen,
Cambridge, MA 02142, USA.. fabienne-mackay@biogen.com
SO EUROPEAN JOURNAL OF IMMUNOLOGY, (1997 Aug) 27 (8) 2033-42.
CY GERMANY: Germany, Federal Republic of
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199709
ED Entered STN: 19971013
Last Updated on STN: 19971013
Entered Medline: 19970930
L13 ANSWER 5 OF 9 MEDLINE
AN 97236575 MEDLINE
DN 97236575 PubMed ID: 9083271
TI Role of T cells in the mediation of Heymann nephritis. II. Identification
AU of Th1 and cytotoxic cells in glomeruli.
AU Penny M J; Boyd R A; Hall B M
CS KIDNEY INTERNATIONAL, (1997 Apr) 51 (4) 1059-68.
SO JOURNAL OF MEDICINE, University of New South Wales, Australia.
CY United States
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; AIDS
EM 199706
ED Entered STN: 19970709
Last Updated on STN: 19970709
Entered Medline: 19970620
L13 ANSWER 6 OF 9 MEDLINE
AN 97079154 MEDLINE
DN 97079154 PubMed ID: 8920886
TI Surface lymphotoxin alpha/beta complex is required for the development of
AU peripheral lymphoid organs.
AU Renmet P D; Browning J L; Mebius R; Mackay F; Hochman P S
CS Biogen Inc., Cambridge, Massachusetts 02142, USA.
SO JOURNAL OF EXPERIMENTAL MEDICINE, (1996 Nov 1) 184 (5) 1999-2006.
Journal code: 2985109R. ISSN: 0022-1007.

CY United States
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199612
 ED Entered STN: 19970128
 Last Updated on STN: 19970128
 Entered Medline: 19961230

L13 ANSWER 7 OF 9 MEDLINE
 AN 94316627
 DN 94316627 Pubmed ID: 7518925
 TI Tumor necrosis factor alpha is an autocrine growth factor for normal human B cells.
 AU Bousfielles V A; Nadler L M; Strominger J L; Goldfeld A E
 CS Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA.
 NC CA-58735 (NCI)
 SO CA47554 (NCI)
 SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. (1994 Jul 19) 91 (15) 7007-11.
 Journal code: 7518925. ISSN: 0027-8424.
 CY United States
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199408
 ED Entered STN: 19940905
 Last Updated on STN: 19980206
 Entered Medline: 19940822

L13 ANSWER 8 OF 9 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1996:351442 BIOSIS
 DN PREV199699073798
 TI Normal development of lymph nodes is disrupted by soluble LT beta receptor-1g fusion protein.
 AU Renneft, P. J.; Browning, J. L.; Hochman, P. S.
 CS Biogen, Inc., 14 Cambridge Cent., Cambridge, MA 02142 USA
 SO European Cytokine Network, (1996) Vol. 7, No. 2, pp. 167.
 Meeting Info.: 6th International Tumor Necrosis Factor Congress Rhodes, Greece May 8-12, 1996
 ISSN: 1148-5493.
 DT Conference
 LA English

L13 ANSWER 9 OF 9 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1978:122347 BIOSIS
 DN BA65:9347
 TI INHIBITION OF HUMAN LYMPHOCYTE MEDIATED MITOGEN INDUCED CYTO TOXICITY OF MURINE L-929 CELL; BY HETEROLOGOUS ANTI HUMAN LYMPHO TOXIN ANTI SERA IN-VITRO.
 AU HISERODT J C; GRAVIGER G A
 CS DEP. MOL. BIOL. BIOCHEM., UNIV. CALIF. IRVINE, IRVINE, CALIF. 92717, USA.
 SO J IMMUNOL. (1977) 119 (2), 374-380.
 CODEN: JOIM33. ISSN: 0022-1767.
 FS BA: OLD
 LA English